Plerixafor Injection 20mg/mL Hematopoietic Stem Cell Mobilizer Single-Dose Vial 2 mL by Amneal (RX)
How to Order:
You will receive instructions on how to create an account along with Rx Ordering Details.
(Note: Acceptable licenses must have Prescriptive Authority in the license issuing state.)
Premium Plerixafor Stem Cell Mobilizer for Hematopoietic Stem Cell Transplantation
Plerixafor Injection 20mg/mL by Amneal Pharmaceuticals is a leading, FDA-approved stem cell mobilizer designed for use in patients with certain types of non-Hodgkin’s lymphoma and multiple myeloma. Plerixafor, in combination with granulocyte-colony stimulating factor (G-CSF), enhances the release of CD34+ hematopoietic stem cells from the bone marrow into peripheral blood for efficient collection and subsequent stem cell transplantation.
With its proven efficacy and high purity, this single-dose 2 mL vial (total 40mg) ensures reliability and safety for adult and pediatric patients undergoing autologous hematopoietic stem cell transplantation (HSCT).
Health Benefits & Clinical Advantages
- Stimulates Rapid Stem Cell Mobilization: Facilitates the movement of hematopoietic stem cells (HSCs) into circulating blood, ensuring optimal cell harvest for autologous transplantation.
- Improves Stem Cell Collection Results: Increases chances of successful transplantation outcomes for patients with lymphoma and multiple myeloma who do not respond adequately to G-CSF alone.
- Optimal for HSCT: Essential adjunct for bone marrow transplant candidates, supporting the recovery and regeneration of blood and immune systems after chemotherapy or radiation.
- High Purity, Consistency, and FDA-Recommended: Manufactured under stringent quality controls by Amneal Pharmaceuticals to ensure consistent performance and patient safety.
- Single-Dose Convenience: Each 2 mL vial contains 20mg/mL (total 40mg) for easy, accurate dosing and reduced medication waste.
Specific FDA-Labeled Uses
- Indications: For use in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma and multiple myeloma.
- Dosage/Administration: Administer subcutaneously as directed by a qualified healthcare professional. Refer to full prescribing information for specific dosing recommendations.
Why Choose Plerixafor Injection by Amneal Pharmaceuticals?
- Industry-Leading Quality: Trusted by healthcare providers for oncology and hematology patients worldwide.
- Enhanced Patient Outcomes: Increases stem cell yields in patients where G-CSF alone is insufficient.
- Streamlined Workflow for Transplant Teams: Single-dose, ready-to-use vial maximizes efficiency and minimizes preparation time.
- Reduced Risk of Collection Failure: Supports improved engraftment and transplantation success rates.
Compliance Information
- Medication: Plerixafor Injection 20mg/mL
- Strength: 20mg/mL
- Volume: 2 mL single-dose vial
- NDC: 70121-1694-02
- UPC: 370121-169420
- Manufacturer: Amneal Pharmaceuticals
- Administration: For subcutaneous injection only; prescription required.
Take Stem Cell Mobilization to the Next Level
Empower your transplant protocols with Plerixafor Injection 20mg/mL by Amneal Pharmaceuticals—a trusted solution for optimal stem cell mobilization and successful autologous hematopoietic stem cell transplantation.
